Year in review 2017: Interstitial lung disease, pulmonary vascular disease and sleep

Year in review 2017: Interstitial lung disease, pulmonary vascular disease and sleep Abbreviations6MWT6‐min walk testAExacute exacerbationBALbronchoalveolar lavageCPAPcontinuous positive airway pressureCPETcardiopulmonary exercise testCTcomputed tomographyCTDconnective tissue diseaseCTD‐ILDCTD‐associated ILDCTEPHchronic thromboembolic PHDLCOdiffusing lung capacity of carbon monoxideFVCforced vital capacityGAPgender age physiologyHPhypersensitivity pneumonitisHRQoLhealth‐related quality of lifeICUintensive care unitIIPidiopathic interstitial pneumoniaILDinterstitial lung diseaseIPFidiopathic pulmonary fibrosisLFALung Foundation of AustraliaMDTmultidisciplinary teamMMFmycophenolateMMP7matrix metalloproteinase 7mPAPmean PA pressureMRCMedical Research CouncilNSIPnon‐specific interstitial pneumonitisNIVnon‐invasive ventilationOSAobstructive sleep apnoeaPApulmonary arteryPAHpulmonary arterial hypertensionPEpulmonary embolismPHpulmonary hypertensionPMportable monitoringPSGpolysomnogramRArheumatoid arthritisRCTrandomized controlled trialRHCright heart catheterizationRituxrituximabRVright ventricleSSc‐ILDscleroderma‐associated ILDTPERtime to peak ejection rateTSANZThoracic Society of Australia and New ZealandVaalveolar volumeINTRODUCTIONSleep‐disordered breathing is common in the community and associated with significant cardiovascular and neurocognitive complications, particularly in vulnerable populations with coexisting morbid conditions. Newer management paradigms are being increasingly implemented to cope with high demand and limited specialist sleep services. These pathways have been primarily used in patients with high clinical risk for obstructive sleep apnoea (OSA), but also need to be extended to other clinical populations including those with co‐morbidities. It is increasingly recognized that while continuous positive airway pressure (CPAP) is very effective in correcting OSA and improving sleepiness, reductions in cardiovascular complications and mortality have not been demonstrated. Poor acceptance and suboptimal use of CPAP undoubtedly contribute to this. Emerging technologies, including device connectivity and web‐based applications, are allowing patients to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Respirology Wiley

Year in review 2017: Interstitial lung disease, pulmonary vascular disease and sleep

Loading next page...
 
/lp/wiley/year-in-review-2017-interstitial-lung-disease-pulmonary-vascular-XA5BvqUh3Q
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Asian Pacific Society of Respirology
ISSN
1323-7799
eISSN
1440-1843
D.O.I.
10.1111/resp.13273
Publisher site
See Article on Publisher Site

Abstract

Abbreviations6MWT6‐min walk testAExacute exacerbationBALbronchoalveolar lavageCPAPcontinuous positive airway pressureCPETcardiopulmonary exercise testCTcomputed tomographyCTDconnective tissue diseaseCTD‐ILDCTD‐associated ILDCTEPHchronic thromboembolic PHDLCOdiffusing lung capacity of carbon monoxideFVCforced vital capacityGAPgender age physiologyHPhypersensitivity pneumonitisHRQoLhealth‐related quality of lifeICUintensive care unitIIPidiopathic interstitial pneumoniaILDinterstitial lung diseaseIPFidiopathic pulmonary fibrosisLFALung Foundation of AustraliaMDTmultidisciplinary teamMMFmycophenolateMMP7matrix metalloproteinase 7mPAPmean PA pressureMRCMedical Research CouncilNSIPnon‐specific interstitial pneumonitisNIVnon‐invasive ventilationOSAobstructive sleep apnoeaPApulmonary arteryPAHpulmonary arterial hypertensionPEpulmonary embolismPHpulmonary hypertensionPMportable monitoringPSGpolysomnogramRArheumatoid arthritisRCTrandomized controlled trialRHCright heart catheterizationRituxrituximabRVright ventricleSSc‐ILDscleroderma‐associated ILDTPERtime to peak ejection rateTSANZThoracic Society of Australia and New ZealandVaalveolar volumeINTRODUCTIONSleep‐disordered breathing is common in the community and associated with significant cardiovascular and neurocognitive complications, particularly in vulnerable populations with coexisting morbid conditions. Newer management paradigms are being increasingly implemented to cope with high demand and limited specialist sleep services. These pathways have been primarily used in patients with high clinical risk for obstructive sleep apnoea (OSA), but also need to be extended to other clinical populations including those with co‐morbidities. It is increasingly recognized that while continuous positive airway pressure (CPAP) is very effective in correcting OSA and improving sleepiness, reductions in cardiovascular complications and mortality have not been demonstrated. Poor acceptance and suboptimal use of CPAP undoubtedly contribute to this. Emerging technologies, including device connectivity and web‐based applications, are allowing patients to

Journal

RespirologyWiley

Published: Jan 1, 2018

Keywords: ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial